PMID- 34980470
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Print)
IS  - 0007-0912 (Linking)
VI  - 128
IP  - 3
DP  - 2022 Mar
TI  - Prognosis and antibody profiles in survivors of critical illness from COVID-19: a 
      prospective multicentre cohort study.
PG  - 491-500
LID - S0007-0912(21)00753-4 [pii]
LID - 10.1016/j.bja.2021.11.024 [doi]
AB  - BACKGROUND: There is a need to assess the long-term outcomes of survivors of 
      critical illness from COVID-19. METHODS: Ninety-two survivors of critical illness 
      from COVID-19 from four hospitals in Hubei Province, China participated in this 
      prospective cohort study. Multiple characteristics, including lung function (lung 
      volumes, diffusing capacity for carbon monoxide, chest computed tomography 
      scores, and walking capacity); immune status (SARS-CoV-2-neutralising antibody 
      and all subtypes of immunoglobulin (Ig) G against SARS-CoV-2, immune cells in 
      response to ex vivo antigen peptide stimuli, and lymphocyte count and its 
      subtypes); liver, coagulation, and kidney functions; quality of life; cognitive 
      function; and mental status, were assessed after 3, 6, and 12 months of 
      follow-up. RESULTS: Amongst the 92 enrolled survivors, 72 (78%) patients required 
      mechanical ventilation. At 12 months, the predicted percentage diffusing capacity 
      of lung for carbon monoxide was 82% (inter-quartile range [IQR]: 76-97%) with a 
      residual volume of 77 (64-88)%. Other lung function parameters and the 6-min walk 
      test improved gradually over time and were almost back to normal by 12 months. 
      The titres of IgG and neutralising antibody to COVID-19 remained high at 12 
      months compared with those of controls who were not infected with COVID-19, 
      although IgG titres decreased significantly from 34.0 (IQR: 23.8-74.3) to 15.0 
      (5.8-24.3) AU ml(-1) (P<0.001), whereas neutralising antibodies decreased from 
      29.99 (IQR: 19.43-53.93) AU ml(-1) at 6 months to 19.75 (13.1-29.8) AU ml(-1) 
      (P<0.001) at 12 months. In general, liver, kidney, physical, and mental functions 
      also improved over time. CONCLUSIONS: Survivors of critical illness from COVID-19 
      show some persistent long-term impairments in lung function. However, a majority 
      of these tests were normal by 12 months. These patients still had detectable 
      levels of neutralising antibodies against SARS-CoV-2 and all types of IgG at 12 
      months, but the levels had declined over this time period. CLINICAL TRIAL 
      REGISTRATION: None.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Yang, Xiao
AU  - Yang X
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China.
FAU - Li, Zhifeng
AU  - Li Z
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China.
FAU - Wang, Binbin
AU  - Wang B
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China.
FAU - Pan, Yunbao
AU  - Pan Y
AD  - Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Jiang, Chaoyun
AU  - Jiang C
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China.
FAU - Zhang, Xingguo
AU  - Zhang X
AD  - Department of Critical Care Medicine, Xishui People's Hospital, Huanggang, Hubei, 
      China.
FAU - Yang, Yadong
AU  - Yang Y
AD  - Department of Critical Care Medicine, Huang Gang Central Hospital, Huanggang, 
      Hubei, China.
FAU - Zhou, Chenliang
AU  - Zhou C
AD  - Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Hu, Chang
AU  - Hu C
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China.
FAU - Zhang, Zhijiang
AU  - Zhang Z
AD  - Department of Preventive Medicine, Wuhan University School of Health Science, 
      Wuhan, Hubei, China.
FAU - Xu, Haibo
AU  - Xu H
AD  - Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      China.
FAU - Liao, Weijin
AU  - Liao W
AD  - Department of Rehabilitation, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Vizcaychipi, Marcela P
AU  - Vizcaychipi MP
AD  - Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery 
      and Cancer, Faculty of Medicine, Imperial College London, London, UK.
FAU - Sanders, Robert D
AU  - Sanders RD
AD  - Department of Anaesthetics & Institute of Academic Surgery, Royal Prince Alfred 
      Hospital, Camperdown, NSW, Australia; Specialty of Anaesthetics, University of 
      Sydney, Camperdown, NSW, Australia.
FAU - Li, Yirong
AU  - Li Y
AD  - Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Ma, Daqing
AU  - Ma D
AD  - Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery 
      and Cancer, Faculty of Medicine, Imperial College London, London, UK. Electronic 
      address: d.ma@imperial.ac.uk.
FAU - Peng, Zhiyong
AU  - Peng Z
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 
      Wuhan, Hubei, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20211126
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Cytokines)
SB  - IM
MH  - Aged
MH  - Antibodies/*blood
MH  - Antibodies, Neutralizing/blood
MH  - COVID-19/blood/*diagnosis/*immunology
MH  - China
MH  - Critical Illness
MH  - Cytokines/blood
MH  - Female
MH  - Humans
MH  - Kidney/physiopathology
MH  - Liver/physiopathology
MH  - Lung/diagnostic imaging/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Quality of Life
MH  - Respiratory Function Tests
MH  - SARS-CoV-2/immunology
MH  - *Survivors
MH  - Tomography, X-Ray Computed
MH  - Walk Test
PMC - PMC8616737
OTO - NOTNLM
OT  - COVID-19
OT  - antibody
OT  - critical illness
OT  - immunity
OT  - lung function
EDAT- 2022/01/05 06:00
MHDA- 2022/03/04 06:00
PMCR- 2021/11/26
CRDT- 2022/01/04 05:53
PHST- 2021/09/28 00:00 [received]
PHST- 2021/11/01 00:00 [revised]
PHST- 2021/11/13 00:00 [accepted]
PHST- 2022/01/05 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2022/01/04 05:53 [entrez]
PHST- 2021/11/26 00:00 [pmc-release]
AID - S0007-0912(21)00753-4 [pii]
AID - 10.1016/j.bja.2021.11.024 [doi]
PST - ppublish
SO  - Br J Anaesth. 2022 Mar;128(3):491-500. doi: 10.1016/j.bja.2021.11.024. Epub 2021 
      Nov 26.